AR and Familial prostate cancer: In contrast to clinically licensed AR antagonists, ARD-61, a novel AR PROTAC, has been shown to efficiently promote on-target AR degradation, elicit more potent antiproliferative and proapoptotic effects, and reduce downstream AR target gene expression in prostate cancer cells.